Literature DB >> 6756833

Treatment of chronic portal--systemic encephalopathy with vegetable and animal protein diets. A controlled crossover study.

M Uribe, M A Márquez, G Garcia Ramos, M H Ramos-Uribe, F Vargas, A Villalobos, C Ramos.   

Abstract

A controlled crossover clinical comparison of 40-g/day and 80-g/day vegetable protein diets vs a 40-g/day meat protein diet plus neomycin-milk of magnesia (as control therapy) was performed on 10 cirrhotic patients with mild chronic portal-systemic encephalopathy. The 40-g vegetable protein diet had a high fiber volume and contained low methionine and low aromatic amino acids. The 80-g vegetable protein diet was rich in branched-chain amino acids and fiber, with a similar content of sulfur-containing amino acids as compared to the 40-g meat protein diet. Serial semiquantitative assessments were done, including mental state, asterixis, number connection tests, electroencephalograms and blood ammonia levels. No patient developed deep coma while ingesting either vegetable protein diet or neomycin-milk of magnesia plus 40-g meat protein diet. A significant improvement in the number connection test times was observed during the 40-g vegetable protein diet (P less than 0.05) and during the 80-g vegetable protein diet (P less than 0.05) as compared to their previous 40-g meat protein--neomycin periods. In addition, during the period of 80-g vegetable protein diet, the patients showed a significant improvement in their electroencephalograms (P less than 0.05). The frequency of bowel movements significantly increased (P less than 0.05) during the 80-g vegetable protein diet period. During the 40-g vegetable protein diet, two cirrhotic--diabetic patients experienced hypoglycemia. Three patients complained of the voluminous 80-g vegetable protein diet. Patients with mild portal--systemic encephalopathy may be adequately controlled with vegetable protein diets as a single therapy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6756833     DOI: 10.1007/bf01391449

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  16 in total

1.  Methionine toxicity in liver disease and its prevention by chlortetracycline.

Authors:  E A PHEAR; B RUEBNER; S SHERLOCK; W H SUMMERSKILL
Journal:  Clin Sci       Date:  1956-02       Impact factor: 6.124

2.  Hyperammonaemia, plasma aminoacid imbalance, and blood-brain aminoacid transport: a unified theory of portal-systemic encephalopathy.

Authors:  J H James; V Ziparo; B Jeppsson; J E Fischer
Journal:  Lancet       Date:  1979-10-13       Impact factor: 79.321

3.  Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy.

Authors:  H O Conn
Journal:  Am J Dig Dis       Date:  1977-06

4.  Mercaptans and dimethyl sulfide in the breath of patients with cirrhosis of the liver. Effect of feeding methionine.

Authors:  S Chen; L Zieve; V Mahadevan
Journal:  J Lab Clin Med       Date:  1970-04

5.  Therapy of portal-systemic encephalopathy: the practical and the promising.

Authors:  F L Weber
Journal:  Gastroenterology       Date:  1981-07       Impact factor: 22.682

6.  Does diet influence human fecal microflora composition?

Authors:  D J Hentges
Journal:  Nutr Rev       Date:  1980-10       Impact factor: 7.110

7.  Treatment of chronic portal systemic encephalopathy with bromocriptine: a double-blind controlled trial.

Authors:  M Uribe; A Farca; M A Márquez; G Garcĭa-Ramos; L Guevara
Journal:  Gastroenterology       Date:  1979-06       Impact factor: 22.682

8.  Ammonia production by intestinal bacteria.

Authors:  A Vince; A M Dawson; N Park; F O'Grady
Journal:  Gut       Date:  1973-03       Impact factor: 23.059

9.  Treatment of chronic portal-systemic encephalopathy with lactose in lactase-deficient patients.

Authors:  M Uribe; M A Márquez; G García-Ramos; V Escobedo; H Murillo; L Guevara; R Lisker
Journal:  Dig Dis Sci       Date:  1980-12       Impact factor: 3.199

10.  Lactose enemas plus placebo tablets vs. neomycin tablets plus starch enemas in acute portal systemic encephalopathy. A double-blind randomized controlled study.

Authors:  M Uribe; J M Berthier; H Lewis; J M Mata; J G Sierra; G García-Ramos; J Ramírez Acosta; M Dehesa
Journal:  Gastroenterology       Date:  1981-07       Impact factor: 22.682

View more
  17 in total

Review 1.  Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management.

Authors:  T Gerber; H Schomerus
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

Review 2.  Nutritional support for liver disease.

Authors:  Ronald L Koretz; Alison Avenell; Timothy O Lipman
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 3.  Dietary and nutritional indications in hepatic encephalopathy.

Authors:  Manuela Merli; Oliviero Riggio
Journal:  Metab Brain Dis       Date:  2008-12-04       Impact factor: 3.584

Review 4.  Sarcopenia in Alcoholic Liver Disease: Clinical and Molecular Advances.

Authors:  Jaividhya Dasarathy; Arthur J McCullough; Srinivasan Dasarathy
Journal:  Alcohol Clin Exp Res       Date:  2017-07-11       Impact factor: 3.455

Review 5.  Traditional management of liver disorders.

Authors:  M Messner; P Brissot
Journal:  Drugs       Date:  1990       Impact factor: 9.546

6.  Protein restriction in hepatic encephalopathy is appropriate for selected patients: a point of view.

Authors:  Douglas L Nguyen; Timothy Morgan
Journal:  Hepatol Int       Date:  2014-09-01       Impact factor: 6.047

Review 7.  Sarcopenia in chronic liver disease: mechanisms and countermeasures.

Authors:  Sophie L Allen; Jonathan I Quinlan; Amritpal Dhaliwal; Matthew J Armstrong; Ahmed M Elsharkawy; Carolyn A Greig; Janet M Lord; Gareth G Lavery; Leigh Breen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-11-25       Impact factor: 4.052

8.  What diet should I recommend my patient with Hepatic Encephalopathy?

Authors:  Jawaid Shaw; Victoria Tate; Jennifer Hanson; Jasmohan S Bajaj
Journal:  Curr Hepatol Rep       Date:  2020-03-05

9.  Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jennifer C Lai; Puneeta Tandon; William Bernal; Elliot B Tapper; Udeme Ekong; Srinivasan Dasarathy; Elizabeth J Carey
Journal:  Hepatology       Date:  2021-09       Impact factor: 17.298

Review 10.  Malnutrition in liver cirrhosis:the influence of protein and sodium.

Authors:  Sareh Eghtesad; Hossein Poustchi; Reza Malekzadeh
Journal:  Middle East J Dig Dis       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.